Medartis Holding AG (SIX: MED): Corporate Profile & Financials

By | Updated on:

Source: Medartis Annual Report 2025

Table of Contents

Quick Facts / Company Snapshot

Metric Details
Company Name Medartis Holding AG
Stock Exchange & Ticker SIX Swiss Exchange (SIX: MED)
Valor / ISIN 38620023 / CH0386200239
Legal Entity Identifier (LEI) 506700VUSP6HG3F28846
Global Headquarters Hochbergerstrasse 60E, CH-4057 Basel, Switzerland
Founding Year 1997
Founder Dr. h.c. Thomas Straumann
Executive Leadership Matthias Schupp (CEO), Dr. Peter Hackel (CFO)
Board Leadership Marco Gadola (Chairman of the Board of Directors)
Total Workforce (Headcount) 1,337 employees (approx. 1,400 across the expanded group)
Manufacturing Footprint 5 production sites: Basel (Switzerland), Warsaw (USA), Archamps (France), Besançon (France), Curitiba (Brazil)
Commercial Presence 12 direct markets; distributor presence in over 50 countries
Core Brands Medartis, KeriMedical, NeoOrtho

Company Overview

Medartis Holding AG is a medical device manufacturer specializing in high-precision solutions for surgical bone fixation and joint replacement. Headquartered in Basel, Switzerland, the company operates across three primary anatomical fields: upper extremities, lower extremities, and the cranio-maxillofacial (CMF) region. Guided by its corporate purpose, “Restoring Quality of Life,” Medartis delivers osteosynthesis implants, instruments, biological surgical solutions, and digital surgical planning services to surgeons, hospitals, and medical clinics globally.

The 2025 financial year served as a transformative milestone as Medartis completed two major corporate transactions: acquiring the remaining 53% equity interest in hand-specialist KeriMedical SA and purchasing a 51% controlling stake in the Brazilian orthopaedic provider NeoOrtho Produtos Ortopédicos S.A. These strategic additions expanded Medartis from a single-brand, centralized entity into a diversified multi-brand corporate group operating under the theme “Three Brands – One Group.” The group combines Swiss precision engineering, specialized joint replacement arthroplasty, and accessible value-tier offerings to extend surgical access across both mature and emerging healthcare markets.

Business Segments

Medartis structures its commercial activities and operational tracking around specific anatomical product clusters and regional reporting segments:

Anatomical Product Categories

  • Upper Extremities: The largest business line within the group, encompassing plate and screw osteosynthesis systems as well as arthroplasty prostheses for the hand, wrist, elbow, and shoulder. In 2025, Upper Extremities generated core net sales of CHF 179.9 million.
  • Lower Extremities: Providing anatomical fixation systems, deformity correction plates, and intramedullary nailing systems for the foot and ankle. Lower Extremities delivered core net sales of CHF 47.3 million in 2025.
  • Cranio-Maxillofacial (CMF) and Others: Dedicated to trauma, orthognathic surgery, mandibular reconstruction, and cranial fixation devices, alongside legacy and digital solutions. In 2025, this segment generated core net sales of CHF 38.8 million.

Geographical Reporting Segments

  • Europe, Middle East, and Africa (EMEA): Medartis’ primary sales generator, incorporating direct sales organizations across Western Europe and third-party distribution in Eastern Europe and the Middle East, alongside KeriMedical’s manufacturing base in France. EMEA generated core net sales of CHF 155.4 million in 2025.
  • North America (NAM / US): Incorporates commercial distribution networks across the United States and manufacturing facilities in Warsaw, Indiana. The US segment delivered core net sales of CHF 50.4 million in 2025.
  • Asia Pacific (APAC): Covering direct subsidiaries in Australia, New Zealand, and Japan, alongside authorized distribution partnerships throughout Southeast Asia. APAC generated core net sales of CHF 33.4 million in 2025.
  • Latin America (LATAM): Encompassing commercial operations across Brazil and Mexico, regional distributor networks, and NeoOrtho’s integrated manufacturing and administrative hub in Curitiba, Brazil. LATAM delivered core net sales of CHF 26.8 million in 2025.

History and Evolution

  • 1997: Medartis AG is founded in Basel, Switzerland, by Dr. h.c. Thomas Straumann, focusing on small-bone internal fixation systems under the ethos “Precision in Fixation.”
  • 2004: Establishment of the International Bone Research Association (IBRA) in Zurich, initiating an enduring educational and scientific collaboration with Medartis.
  • 2018: Medartis Holding AG executes its Initial Public Offering (IPO) on the SIX Swiss Exchange.
  • 2020: Medartis introduces its CMX digital case planning service for patient-specific surgical guides and custom implants; acquires an initial 25% minority interest in Geneva-based KeriMedical SA.
  • 2022: Acquisition of Nextremity Solutions Inc. (NSI) in Warsaw, Indiana, securing a dedicated manufacturing, product development, and mechanical testing site in the United States.
  • 2023: Equity interest in KeriMedical SA increased to 47%.
  • 2025: Milestone corporate transformation year:
    • Completed the acquisition of 100% of KeriMedical following US FDA approval of the flagship TOUCH CMC 1 prosthesis.
    • Acquired a 51% controlling stake in NeoOrtho Produtos Ortopédicos S.A., securing immediate manufacturing and commercial access to the Latin American value market.
    • Acquired the Avenger Radial Head System from In2Bones Global to expand upper extremity trauma and arthroplasty portfolios.
    • Entered into a definitive agreement to acquire CADskills, a Belgian pioneer in patient-specific implants (PSI) and titanium 3D printing.

Products and Services

Medartis engineers anatomy-specific, low-profile fixation and arthroplasty devices designed to restore mobility while shortening surgical times:

Core Fixation Technologies

  • TriLock: A proprietary multidirectional, angular-stable locking system that provides rigid screw-to-plate fixation without external threading interference.
  • HexaDrive: An engineered screw-head interface offering self-retaining friction, optimized torque transmission, and reduced cam-out risks.
  • SpeedTip: Cutting geometries engineered for immediate bone penetration without the necessity of pre-drilling.

Joint Replacement & Specialty Arthroplasty

  • TOUCH CMC 1 Prosthesis: Dual-mobility basal thumb joint replacement designed to treat severe carpometacarpal rhizarthrosis. Miniaturizing total hip mechanics, the prosthesis preserves grip strength and range of motion.
  • Avenger Radial Head System: Modular elbow arthroplasty solution enabling surgeons to choose between prosthetic replacement and osteosynthesis fixation during complex elbow trauma.
  • KeriFlex & MOTEC: Flexible silicone finger joint replacements and modular wrist arthroplasty systems.

Digital Planning & Patient-Specific Solutions

  • CMX Portal: An integrated web-based case planning environment enabling clinicians to upload CT scans, collaborate directly with clinical biomedical design engineers, and receive patient-matched cutting guides, 3D bone models, and custom-milled titanium plates.
  • Medartis ONE: A mobile-optimized enterprise digital platform that combines surgical techniques, educational modules, and technical product documentation for real-time operating room and clinical support.

Upcoming Pipeline Systems (2026 Scheduled Launches)

  • PentaLock 3.5 Proximal Humerus System: Asymmetric shoulder fracture fixation featuring an anatomical plate rim that avoids deltoid insertion and includes an optional spiral calcar support blade.
  • Clavicle Hook Plates: Redesigned fixation for acromioclavicular joint dislocations and lateral clavicle fractures.
  • Fibula Nail: Minimally invasive intramedullary ankle trauma fixation featuring a hinged outrigger for unobstructed fracture visualization.
  • Titan Nail System: Specialized intramedullary fixation system for transverse and oblique metacarpal and phalangeal fractures.
  • CMX TriLock 3.5 Custom Plates: Tailored corrective osteotomy plates for supramalleolar ankle corrections.

Brand Portfolio

The Medartis Group consolidates three distinct commercial brand identities:

  • Medartis: The flagship premium brand, recognized globally for Swiss precision-engineered titanium osteosynthesis plates, cortical screws, and the APTUS and MODUS product families across upper limb, lower limb, and CMF surgeries.
  • KeriMedical: The hyper-specialized distal extremity brand focused exclusively on joint reconstruction, soft tissue fixation, and arthroplasty for hand and wrist pathologies, anchored by the TOUCH thumb system.
  • NeoOrtho: The accessible value brand focused on cost-effective, clinically validated trauma, spine, and CMF fixation devices, designed to compete efficiently in public hospital tenders and regional emerging healthcare segments.

Geographical Presence

The Medartis Group maintains administrative, manufacturing, and commercial infrastructure across major medical device territories:

  • Production Network: Five specialized facilities:
    • Basel, Switzerland: Group headquarters, automated CNC milling, turning, cleanroom packaging, and global R&D.
    • Warsaw, Indiana, USA: Domestic manufacturing center supporting localized plate and screw fabrication, advanced prototyping, and mechanical testing.
    • Archamps, France: KeriMedical’s R&D, commercial logistics, cleanroom packaging, and surgeon training academy.
    • Besançon, France: KeriMedical’s precision micromechanics production facility.
    • Curitiba, Paraná, Brazil: NeoOrtho’s modern 6,800 square meter modular manufacturing plant.
  • Direct Commercial Subsidiaries: Wholly owned legal entities operating across 12 countries: Switzerland, Germany, Austria, France, the United Kingdom, Spain, Poland, the United States, Australia, New Zealand, Japan, and Mexico.
  • Global Distribution: Sales reach extending to over 50 additional global markets through exclusive master distributors and qualified medical logistics partners across Latin America, the Middle East, and the Asia-Pacific region.

Board of Directors and Leadership Team

Board of Directors

  • Marco Gadola: Independent Chairman of the Board of Directors
  • Dr. h.c. Thomas Straumann: Vice Chairman, Founder, and Major Shareholder
  • Willi Miesch: Non-Executive Member (Chair of Strategy & Innovation Committee; Former CEO 1998–2019)
  • Damien Tappy: Non-Executive Member (Chair of Human Resources & Compensation Committee)
  • Nadia Tarolli Schmidt: Non-Executive Member (Chair of Finance & Audit Committee; Board ESG Delegate)
  • Ciro Roemer: Non-Executive Member
  • Martha Shadan: Non-Executive Member
  • Jennifer Dean: Non-Executive Member (Term ending AGM 2026; Yang Xu proposed as successor)

Executive Management Board (EMB)

  • Matthias Schupp: Chief Executive Officer
  • Dr. Peter Hackel: Chief Financial Officer (effective 1 January 2026; succeeding Dr. Dirk Kirsten)
  • Caroline Knoeri: Chief Human Resources Officer
  • Mareike Loch: President EMEA
  • Marc Ammann: Executive Vice President of R&D and Innovation
  • Mario Della Casa: Chief Operating Officer
  • David Thoni: US President

Our ability to deliver these results whilst managing substantial internal change underlines the predictability of our trauma business, the agility of our teams, the diversity of our portfolio, and the quality of our execution.

Marco Gadola, Chairman, and Matthias Schupp, CEO

Future Strategy

Medartis executes its strategic roadmap under the overarching “Head to Toe” corporate strategy, addressing six specific execution clusters:

  • Accelerating the US Business: Executing the commercial expansion of the newly FDA-approved TOUCH thumb arthroplasty prosthesis, expanding direct surgeon training programs, and scaling localized manufacturing at the Warsaw facility via “Project Flash” to mitigate international tariffs and supply chain delays.
  • Expanding KeriMedical Worldwide: Broadening direct and distributor sales of joint replacement portfolios beyond core French and German hubs into the United Kingdom, the United States, Australia, and selected Asian markets.
  • Implementing the Latin American Value Strategy: Scaling NeoOrtho’s footprint across Latin America (Mercosul bloc, Colombia, Argentina, and Chile), while executing the “Cold Fusion” administrative integration in Curitiba to optimize back-office functions and operational synergies.
  • Driving Regional Market Share Gains: Expanding specialized plate indications, converting surgeon accounts through direct sales structures (such as in Japan and Mexico City), and securing institutional tenders across EMEA and APAC.
  • Advancing Innovation and Digitalization: Finalizing the integration of CADskills’ patient-specific additive titanium 3D printing capabilities, driving adoption of the CMX surgical planning software, and addressing complex clinical niches in CMF and extremity trauma.
  • Cash Flow and Operational Discipline: Transitioning executive compensation incentives to 100% Performance Stock Units linked to cash flow generation and relative Total Shareholder Return, while improving set management efficiency and reducing balance sheet capital intensity.

Key Strengths

  • Proprietary Engineering Moats: Patented fixation platforms including the TriLock multidirectional locking mechanism and HexaDrive self-retaining screw interface establish high clinical switching barriers.
  • Multi-Tier Market Access: Operating three complementary brands allows Medartis to serve premium surgical centers with Swiss-made implants while simultaneously contesting cost-sensitive public hospital tenders via NeoOrtho.
  • Strategic Clinical Education Pipeline: Global collaboration with the International Bone Research Association (IBRA) provides access to a certified international bioskills training network encompassing over 70 centers in 20 countries.
  • Localized Manufacturing Agility: Five specialized production facilities across Europe, North America, and South America reduce operational bottlenecks, provide local inventory responsiveness, and buffer against global trade friction.
  • Dual-Mobility Joint Replacement Innovation: First-mover status with the US FDA Premarket Approval (PMA) for dual-mobility carpometacarpal thumb implants (TOUCH), opening an addressable market segment largely unaddressed by large orthopaedic conglomerates.

Key Challenges and Risks

  • Foreign Exchange Sensitivity: With its primary corporate and manufacturing expense base denominated in Swiss francs (CHF) and significant international sales generated in USD, EUR, and AUD, Medartis faces ongoing translational and transactional currency headwinds.
  • Customs Tariffs and Protectionism: Evolving global trade policies, particularly reciprocal tariffs implemented in the United States, create direct pressure on gross margins, necessitating capital-intensive transfers of CNC turning and milling machinery to Warsaw, Indiana.
  • Sales Channel Transition in the United States: Restructuring the US commercial distribution network—which involved replacing approximately half of its distribution partners and severing ties with its largest Florida distributor in 2025—entails short-term customer transition risks before the expanded 65-partner network reaches full productivity.
  • Stringent Regulatory Environments: Evolving requirements under the EU Medical Device Regulation (MDR) and the US FDA Premarket Approval (PMA) pathway impose substantial continuous compliance expenses, extensive clinical documentation, and long notified-body review timelines.
  • Post-Merger Integration Complexity: Simultaneous operational, IT, and cultural integration of KeriMedical in France and NeoOrtho in Brazil requires rigorous governance to realize projected back-office and distribution synergies without disrupting active sales momentum.

Conclusion and Strategic Outlook

The transformation of Medartis into a multi-brand medical device group positions the company to compete across an addressable market exceeding CHF 10 billion. By combining its heritage in Swiss precision osteosynthesis with KeriMedical’s arthroplasty platforms and NeoOrtho’s value-tier manufacturing scale, the company has broadened its customer reach and geographic diversity. Backed by renewed executive leadership, disciplined capital allocation, and an expanding pipeline of anatomy-specific solutions, Medartis is structured to advance its market share across extremities and cranio-maxillofacial surgery worldwide.

Official Site

Official corporate website: https://www.medartis.com

Income Statement / Profit and loss

Metric (in CHF thousands) FY 2025 FY 2024 YoY Growth (%)
Net revenue 269’257 224’831 +19.76%
Cost of goods sold (64’927) (46’148) +40.69%
Gross profit 204’330 178’683 +14.35%
Selling and distribution (128’181) (101’932) +25.75%
Research and development (31’436) (43’104) -27.07%
General and administration (44’543) (38’573) +15.48%
Share of results of associate 978 638 +53.29%
Other operating income 25’775 12’153 +112.09%
Other operating expense (911) – –
Operating profit 26’011 7’865 +230.72%
Finance income 1’313 1’436 -8.57%
Finance expense (14’536) (6’802) +113.70%
Profit before taxes 12’788 2’499 +411.72%
Income tax (expense)/income (3’453) 1’029 +235.57%
Net income 9’336 3’528 +164.63%
Attributable to Medartis Holding AG shareholders 8’349 3’528 +136.65%
Attributable to non-controlling interests 987 – –

Balance sheet

Metric (in CHF thousands) 31 December 2025 31 December 2024 YoY Growth (%)
Cash and cash equivalents 32’966 138’686 -76.23%
Accounts receivable trade 50’337 41’419 +21.53%
Accounts receivable other 8’640 4’800 +80.00%
Income tax receivables 1’928 673 +186.48%
Inventories 98’198 79’148 +24.07%
Prepaid expenses 3’212 1’221 +163.06%
Total current assets 195’282 265’945 -26.57%
Property, plant and equipment 66’971 51’269 +30.63%
Right-of-use assets 27’089 24’681 +9.76%
Intangible assets 241’419 51’861 +365.51%
Investment in associate – 34’379 –
Financial assets 1’279 790 +61.90%
Deferred tax assets 27’882 31’036 -10.16%
Total non-current assets 364’640 194’016 +87.94%
Total assets 559’922 459’961 +21.73%
Accounts payable trade 16’089 8’856 +81.67%
Accounts payable other 24’448 19’534 +25.16%
Income tax payables 1’279 327 +291.13%
Accrued expenses 5’509 3’802 +44.90%
Current financial debt and other financial liabilities 26’575 7’784 +241.41%
Contingent consideration liabilities (current) 11’979 8’146 +47.05%
Provisions (current) 2’294 2’570 -10.74%
Total current liabilities 88’173 51’018 +72.83%
Non-current financial debt and other financial liabilities 131’543 113’443 +15.96%
Contingent consideration liabilities (non-current) 19’500 990 +1869.70%
Liabilities towards non-controlling interests 16’357 – –
Provisions (non-current) 2’744 2’827 -2.94%
Employee benefit obligation 12’731 17’058 -25.37%
Deferred tax liabilities 13’002 4’979 +161.14%
Total non-current liabilities 195’876 139’297 +40.62%
Total liabilities 284’049 190’315 +49.25%
Share capital 2’726 2’719 +0.26%
Capital reserves 293’007 290’499 +0.86%
Treasury shares (240) (240) 0.00%
Currency translation adjustments (11’439) (4’035) +183.49%
Retained earnings (8’182) (19’297) -57.60%
Equity attributable to Medartis Holding AG shareholders 275’872 269’646 +2.31%
Non-controlling interests – – –
Total equity 275’872 269’646 +2.31%
Total liabilities and equity 559’922 459’961 +21.73%

Cash flow

Metric (in CHF thousands) FY 2025 FY 2024 YoY Growth (%)
Net cash from operating activities 34’817 32’072 +8.56%
Cash payments to acquire property, plant and equipment (18’670) (7’172) +160.32%
Proceeds from disposals of property, plant and equipment 118 336 -64.88%
Cash payments to acquire intangible assets (6’805) (3’920) +73.60%
Additions to financial assets (59) – –
Disposals to financial assets – 207 –
Acquisition of subsidiaries, net of cash acquired (108’846) – –
Cash payment contingent consideration liabilities (12’000) (8’513) +40.96%
Net cash used for investing activities (146’262) (19’062) +667.30%
Proceeds from capital increases (net after transaction costs) 709 629 +12.72%
Proceeds from convertible bonds (net after transaction costs) – 112’398 –
Proceeds from borrowings 23’997 – –
Repayment current financial debt (4’420) (925) +377.84%
Repayment of lease liabilities (9’009) (6’900) +30.57%
Interest paid on lease liabilities (642) (719) -10.71%
Interest paid (3’803) (3’899) -2.46%
Net cash from/(used for) financing activities 6’833 100’583 -93.21%
Net change in cash and cash equivalents (104’612) 113’593 -7.91%
Cash and cash equivalents at 1 January 138’686 25’201 +450.32%
Net effect of currency translation on cash and cash equivalents (1’108) (109) +916.51%
Cash and cash equivalents at 31 December 32’966 138’686 -76.23%

Subsidiaries & Joint Ventures

  • Medartis AG, Switzerland (Basel): Share capital CHF 1’000’000; 100% investment (direct).
  • Mimedis AG in liquidation, Switzerland (Basel): Share capital CHF 50’000; 100% investment (indirect).
  • Keri Medical SA, Switzerland (Geneva): Share capital CHF 4’703’130; 100% investment (indirect).
  • Keri Medical France SAS, France (Archamps): Share capital EUR 5’000’000; 100% investment (indirect).
  • Keri Medical GmbH, Germany (Mainz): Share capital EUR 100’000; 100% investment (indirect).
  • Medovent GmbH, Germany (Mainz): Share capital EUR 154’353; 100% investment (indirect).
  • Medartis GmbH, Germany (Umkirch): Share capital EUR 51’129; 100% investment (indirect).
  • Medartis Iberia SL, Spain (Barcelona): Share capital EUR 3’000; 100% investment (indirect).
  • Medartis S.a.r.l., France (Lyon): Share capital EUR 15’000; 100% investment (indirect).
  • Medartis International Finance SAS, France (Lyon): Share capital EUR 1; 100% investment (indirect).
  • Medartis GmbH, Austria (Vienna): Share capital EUR 35’000; 100% investment (indirect).
  • Medartis Co. Ltd., Japan (Tokyo): Share capital JPY 10’000’000; 100% investment (indirect).
  • Medartis Ltd, UK (Derby): Share capital GBP 3’700’000; 100% investment (indirect).
  • Medartis Do Brasil Participações Ltda., Brazil (São Paulo): Share capital BRL 25’157’562; 100% investment (indirect).
  • Medartis Importação E Exportação Ltda., Brazil (São Paulo): Share capital BRL 18’000’000; 100% investment (indirect).
  • NEOORTHO Produtos Ortopédicos S.A., Brazil (Curitiba): Share capital BRL 92’519’493; 51% investment (indirect).
  • Medartis Inc, USA (Delaware): Share capital USD 10; 100% investment (indirect).
  • Lakeland Technology Holdings LLC, USA (Warsaw): Share capital USD 0.01; 100% investment (indirect).
  • Medartis S.A. de C.V, Mexico (Mexico): Share capital MXN 100’000; 100% investment (indirect).
  • Medartis Sp.z.o.o, Poland (Wroclaw): Share capital PLN 200’000; 100% investment (indirect).
  • Medartis Australia and New Zealand Pty Ltd, Australia (Albion): Share capital AUD 1’203’000; 100% investment (indirect).
  • Medartis New Zealand Ltd, New Zealand (Auckland): Share capital NZD 1’000; 100% investment (indirect).

Other Investments & Holdings

  • CADskills (Belgium): Definitive agreement entered into to acquire this specialist in personalised implant solutions and titanium printing; closing subject to conditions including Foreign Direct Investment screening in Belgium.
  • Keri Medical SA: Previously held 47% associate investment remeasured at fair value upon step acquisition to 100% in July 2025 (investment in associate balance reduced from CHF 34’379 thousand at 31 December 2024 to CHF 0 at 31 December 2025).

Physical properties

  • Basel, Switzerland: Global headquarters, primary R&D, and manufacturing facilities (Hochbergerstrasse 60E).
  • Warsaw, Indiana, USA: Development, manufacturing, and distribution site.
  • Archamps, Haute-Savoie, France: KeriMedical research and development, production, logistics, and training facility.
  • Besançon, France: KeriMedical manufacturing and micromechanics production facility.
  • Curitiba, Paraná, Brazil: NeoOrtho administrative headquarters and modular manufacturing plant (second phase encompassing 6’800 square metres of production space).

Investments and capital expenditure

  • Capital expenditures on property, plant and equipment: CHF 18’670 thousand in FY 2025 (FY 2024: CHF 7’172 thousand).
  • Capital expenditures on intangible assets: CHF 6’805 thousand in FY 2025 (FY 2024: CHF 3’920 thousand).
  • Set investments: CHF 11’400 thousand invested into new sets in FY 2025 (CHF 5’600 thousand in implants inventory and CHF 5’800 thousand in instruments and containers PP&E).
  • Manufacturing machinery additions: CHF 5’100 thousand in FY 2025 (largely direct leasing).
  • Curitiba facility construction: CHF 6’700 thousand invested into the new NeoOrtho production location.
  • Total Research and Development expenditure: CHF 31’436 thousand in FY 2025 (FY 2024: CHF 43’104 thousand).
  • Capitalized development expenditures: CHF 12’463 thousand carrying value as of 31 December 2025 (31 December 2024: CHF 8’961 thousand).

Shareholding pattern / Ownership

Direct holder Shares % Stake Previous % Stake
Dr. h.c. Thomas Straumann, Riehen, Switzerland 5’435’036 39.9% Not disclosed
Nordflint Capital Partners Fondsmaeglerselskab A/S, Copenhagen 1’183’002 8.7% Not disclosed
Endeavour Medtech Growth LP, Guernsey, Channel Islands 874’490 6.4% Not disclosed
NexMed Holding AG, Meggen, Switzerland 785’962 5.8% Not disclosed
Willi Miesch, Küssnacht am Rigi, Switzerland 564’340 4.1% Not disclosed

Frequently Asked Questions

What are the primary medical fields served by Medartis?
Medartis develops, manufactures, and distributes surgical fixation and reconstruction systems for three primary anatomical areas: upper extremities (hand, wrist, elbow, shoulder), lower extremities (foot, ankle), and the cranio-maxillofacial (CMF) region.
Which companies and brands comprise the Medartis Group?
The Medartis Group operates under three distinct brand identities: Medartis (premium Swiss precision osteosynthesis fixation systems), KeriMedical (specialized hand and wrist joint replacement arthroplasty), and NeoOrtho (accessible value-tier trauma, spine, and orthopaedic implants).
What is the clinical significance of the KeriMedical TOUCH prosthesis?
The TOUCH CMC 1 prosthesis is a dual-mobility implant designed for the treatment of advanced osteoarthritis at the base of the thumb (rhizarthrosis). It miniaturizes the biomechanical mobility concepts of total hip replacements, preserving natural thumb length, joint stability, and grip strength compared to traditional bone resection surgeries.
Where are Medartis’ primary manufacturing facilities located?
The group operates five production facilities across three continents: Basel in Switzerland, Warsaw in Indiana (USA), Archamps and Besançon in France, and Curitiba in Paraná (Brazil).
What is the role of IBRA in relation to Medartis?
The International Bone Research Association (IBRA) is an independent non-profit scientific and educational organization founded in 2004. Medartis serves as its primary industry partner, collaborating on biomechanical research, clinical studies, surgical fellowship programs, and hands-on surgical training courses across more than 70 training centers globally.